" class="no-js "lang="en-US"> BioCina Has Been Awarded Grants to Develop mRNA Vaccines
Sunday, March 03, 2024

BioCina Has Been Awarded Grants to Develop mRNA Vaccines

BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $5.0m AUD grant under the Federal Government’s Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for manufacture of precision mRNA vaccines.

The grant has been awarded by the Australian Government’s National Health and Medical Research Council (NHMRC), and will be matched by the South Australian Government to support a five-year collaborative project with a total value of over $10.0m AUD, working with industry and academic partners, Cytiva and the University of Adelaide.

The project, commencing almost immediately, helps BioCina address the post-pandemic mRNA demand for specific and essential attributes of new personalized RNA products. Australia currently lacks domestic manufacturing of mRNA products under accredited pharmaceutical GMP. This MRFF grant strengthens linkages between commercial lead BioCina Pty Ltd, industry partner Cytiva, as well as expands discovery research in microfluidic chip parallel manufacturing of mRNA based therapeutic vaccines with world-class experts from the University of Adelaide. Outcomes of this grant will extend mRNA manufacturing and analytical capabilities of BioCina’s GMP facility to all clinical phases and commercial supply and deliver new to market automated microfluidics technology for manufacture of mRNA therapeutic vaccines, which will fill a significant technology gap in the personalised mRNA vaccines market.

“I’m very proud that BioCina has earned this MRFF grant. This funding, along with additional financial support from the South Australian Government, aims to deliver two complementary outcomes. The first is an increase in mRNA manufacturing and associated analytical capability at BioCina, and the second is a microfluidics-based device for parallel manufacture at the small scales required for the personalized therapeutic vaccines market. This will increase capacity to produce mRNA pharmaceuticals, including vaccines, from initial fermentation of DNA plasmids to formulated mRNA-Lipid Nanoparticle (LNP) complexes for administration in clinical trials,” said BioCina CEO, Mark W. Womack.

BioCina Executive Chairman and Founder, Ian Wisenberg added, “This project increases capacity to produce mRNA-LNP at the BioCina site, as well as add end-to-end capacity to manufacture mRNA products. This expansion of manufacturing capabilities allows BioCina to service a larger section of the global market and ensure that Australia has population-scale onshore mRNA vaccine manufacturing capabilities.”

The University’s Deputy Vice-Chancellor and Vice-President (Research), Professor Anton Middelberg commented, “although ambitious, the research and development project has been carefully designed with a reasonable feasibility/gain/risk balance and it is strongly supported by the unique interdisciplinary and complementary expertise of the chief investigators (CIs). The proposed research is very closely aligned with the CIs’ expertise. The goal of this work is to introduce a start-to-finish manufacturing solution for personalised mRNA-LNP therapeutics that is world-class, in a timely manner that can service Australian and international companies.”

The Hon. Nick Champion, Minister for Trade and Investment, South Australian Government says, “BioCina’s mRNA Centre of Excellence in South Australia will be Australia’s first mRNA capability able to offer end-to-end client services to support the entire mRNA manufacturing and development process. We’re delighted to support BioCina’s manufacturing leadership and Australia’s sovereign mRNA vaccine supply capabilities.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more